Acorda Therapeutics, Inc. announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced total revenue was USD 38.160 million compared to USD 50.497 million a year ago. Operating loss was USD 78.395 million compared to operating Income of USD 14.486 million a year ago. Net loss was USD 83.048 million compared to net income of USD 65.660 million a year ago. Basic loss per share from continuing operations was USD 9.82 compared to basic earnings per share from continuing operations of USD 8.27 a year ago. Diluted loss per share from continuing operations was USD 9.82 compared to diluted earnings per share from continuing operations of USD 8.26 a year ago. For the full year, total revenue was USD 152.967 million compared to USD 192.408 million a year ago. Operating loss was USD 78.076 million compared to USD 311.632 million a year ago. Net loss was USD 99.594 million compared to USD 272.966 million a year ago. Basic loss per share from continuing operations was USD 12.32 compared to USD 34.43 a year ago.